What Плетакс Treats: Main Uses and Benefits

Плетакс (Cilostazol) is commonly used to help with symptomatic relief in individuals with Peripheral Arterial Disease (PAD). The medication is utilized to help with symptoms related to physical discomfort during activity. This application addresses these symptomatic patterns.

---

Symptomatic Relief and Functional Support

Плетакс is commonly used to help with conditions characterized by periods of heightened symptoms, specifically symptomatic Intermittent Claudication. This includes managing the pain, cramping, or aching in the legs that are symptoms related to physical discomfort and interfere with daily functioning. In these situations, the medication helps address symptom clusters that create noticeable physiological strain and restrict mobility.

The overall benefit contributes to easing the overall symptom load and assists with maintaining functional stability.

“The therapeutic goal is to support the patient's ability to cope more steadily with symptom fluctuations.”

---

Quick Fact

Quick Fact: Relief for Exertional Leg Pain

Плетакс is applied in addressing conditions marked by significant symptomatic burden, where the ability to walk is limited due to physical discomfort during exertion. It supports the patient during difficult episodes by easing distress related to limited mobility and is relevant for managing symptoms that interfere with daily comfort.

Regulatory References

1. NIH MedlinePlus overview on Cilostazol

Official Eligibility and Non-Eligibility for Плетакс (Cilostazol)

Cilostazol is officially permitted for use in adult patients diagnosed with Peripheral Arterial Disease (PAD) experiencing symptomatic Intermittent Claudication. Its use is strictly defined by regulatory guidelines that outline specific populations who are prohibited from taking the medicine.

Population Status	Eligibility Rule (Official Labeling)
Populations Contraindicated (Absolute Ban)	Use is contraindicated in patients with Congestive Heart Failure (CHF) of any severity; recent myocardial infarction or unstable angina (within 6 months); or a history of severe tachyarrhythmia or QTc interval prolongation.
Organ Function Restrictions	The medicine is contraindicated in patients with severe renal impairment (Creatinine Clearance leq 25 mL/min) and moderate or severe hepatic impairment.
Bleeding Risk Restrictions	Use is contraindicated for patients with any known predisposition to bleeding, including active peptic ulceration, recent hemorrhagic stroke, or those taking two or more antiplatelet/anticoagulant agents.
Age and Physiological State	Safety and effectiveness have not been established in pediatric patients (under 18 years), leading to a non-recommendation. Use is contraindicated during pregnancy and breastfeeding.

These eligibility criteria establish clear regulatory boundaries, formally excluding patient populations with high-risk cardiovascular conditions, severe organ dysfunction, or heightened hemorrhagic risk as defined in government-approved prescribing information.

Interactions with other medicines and products

Official Interaction Restrictions

The interaction profile for Cilostazol (Плетакс) is primarily defined by formal restrictions related to its metabolic pathway and its pharmacodynamic activity. Co-administration is formally contraindicated with both potent inhibitors of the CYP3A4 enzyme (such as ketoconazole and erythromycin) and potent inhibitors of the CYP2C19 enzyme (such as omeprazole). These drug-drug interactions lead to a significant increase in the plasma concentration (exposure) of Cilostazol and its active metabolite, which is explicitly prohibited by regulatory authorities.

---

Pharmacodynamic and Substance Interactions

Cilostazol's antiplatelet action results in an additive inhibitory effect on platelet aggregation when co-administered with other antiplatelet agents (e.g., aspirin or clopidogrel) or anticoagulants (e.g., warfarin). The use of Cilostazol is also contraindicated with any other Phosphodiesterase Type 3 (PDE3) Inhibitor due to the risk of combined cardiovascular effects.

Administration restrictions also apply to specific substances: a high-fat meal is documented to increase the maximum plasma concentration (C max) by approximately 90%. Furthermore, grapefruit juice intake is noted to increase plasma levels due to its inhibitory effect on the CYP3A4 enzyme. The use of Cilostazol is also contraindicated in patients with moderate or severe hepatic impairment due to the resulting exposure risk.

How Плетакс Works

The mechanism of action for Плетакс (Cilostazol) centers on the modulation of enzyme-mediated signaling pathways to produce dual physiological effects: vasodilation and antiplatelet action.

Плетакс functions as a selective inhibitor of the enzyme Phosphodiesterase 3 (PDE3), which is primarily located in vascular smooth muscle cells and platelets. By blocking PDE3, the drug prevents the metabolism of the critical cellular messenger cyclic AMP (cAMP), causing a resulting increase in intracellular cAMP concentration in these targeted cells.

The elevated cAMP levels in the vascular smooth muscle cells cause them to relax, leading to the physiological effect of vasodilation (widening) of peripheral blood vessels. Concurrently, the rise in cAMP within platelets interferes with the signaling necessary for their activation. This antiplatelet action reduces platelet stickiness and decreases their aggregation potential, promoting unobstructed blood flow through the vessels.

How to Use Плетакс: Administration Guidelines

Плетакс (Cilostazol) follows defined parameters to ensure proper exposure and management. The medicine is consistently delivered via the oral route using the available 50 mg and 100 mg tablets.

Dosing and Frequency

The standard regimen for adults is 100 mg taken twice daily (b.i.d.). This standard dose is adjusted when the medicine is used alongside specific other drugs. If strong or moderate inhibitors of the CYP3A4 or CYP2C19 enzymes are used concurrently, the dosage is reduced by half, to 50 mg twice daily.

Administration Conditions and Duration

A key aspect regarding the intake procedure is the time-relationship to food. Плетакс is taken on an empty stomach, meaning administration occurs at least 30 minutes before or 2 hours after a meal, typically breakfast and dinner. This timing is necessary for the drug’s intended absorption profile.

Treatment is initiated by physicians experienced in the management of the underlying condition. Under the established therapeutic trial duration, patients are treated for up to 12 weeks (three months) to assess the full benefit. If symptoms remain unimproved after this three-month period, the treatment is discontinued.

For certain patient groups, such as older adults and individuals with mild hepatic impairment or non-severe renal impairment (creatinine clearance greater than 25 mL/min), no specific dosage adjustment is required from the standard regimen.

Research evidence / Overview of Studies for Плетакс

Evidence for Use in Symptomatic Intermittent Claudication

The evidence base for Плетакс (Cilostazol) centers on clinical research that was studied for use in clinical contexts involving Symptomatic Intermittent Claudication (leg pain or cramping during walking, a key sign of Peripheral Arterial Disease or PAD). Research has primarily utilized Randomized Controlled Trials (RCTs), which compare how functional walking capacity was assessed in the context of the medicine against a placebo (an inactive treatment).

Researchers primarily measured outcomes related to physical functioning, including assessments of the Initial Claudication Distance (ICD) and the Absolute Claudication Distance (ACD). These outcomes were assessed using standardized treadmill tests over defined time intervals, typically lasting 12 to 24 weeks.

The findings describe patterns observed in the measurements of the functional walking endpoints, assessed against the measurements recorded in the placebo group. Research also examined patient-reported outcomes describing perceived discomfort, and some trials described patterns observed in the measured results of physical functioning domains. Research also examined outcomes related to systemic or functional imbalance, specifically monitoring measured changes in blood lipids (including decreases in triglycerides and increases in HDL cholesterol).

---

Long-Term Studies and Follow-Up Data

The majority of the research evaluating outcomes related to walking distance and quality of life had follow-up durations that were limited, typically covering the short-term to intermediate-term (a few months).

Evidence is limited for long-term outcomes, meaning that the research exploring the long-term observation of endpoints such as major vascular events—including the risk of needing an amputation, revascularization procedures, or experiencing a stroke or heart attack—is not fully established.

---

What is Still Uncertain About Плетакс Research

The scientific body of evidence highlights what is known and what is still uncertain about this medicine. A primary limitation is that evidence regarding the data on major, life-altering events remains very limited. Research in this area is ongoing, but definitive long-term effects are not fully established.

Some scientific reviews of the evidence point out that the evidence quality varies across studies, noting that some findings were mixed or the certainty remains low for certain endpoints. For example, while the studies report measurements of the functional walking endpoints, the exact clinical significance of these measured changes for the patient's daily life is a subject of ongoing scientific discussion. The research provides context but not individual predictions, as the study results reflect the specific conditions under which they were conducted.

Common questions about Плетакс (FAQ)

---

Q: How should I dispose of any unused or expired tablets?

According to official regulatory guidance, any unused or expired tablets should be disposed of carefully. A drug take-back program may be used if one is available in the area, or the medicine can be mixed with an undesirable substance, like used coffee grounds or dirt, before being placed in household trash. Regulatory disposal instructions advise against flushing the tablets down the toilet.

---

Q: Can I eat food when I take my dose of Cilostazol?

Official administration instructions state that this medication must be taken on an empty stomach. This timing typically means administration is necessary at least 30 minutes before a meal or 2 hours after a meal, such as breakfast or dinner. This procedure is specified to ensure the drug's intended absorption profile.

---

Q: What is the mechanism by which it increases blood flow?

Studies and official product information indicate that the active ingredient, Cilostazol, works by inhibiting an enzyme called Phosphodiesterase 3 (PDE3). This inhibition causes a dual effect: it helps relax and widen blood vessels (vasodilation) and reduces the tendency of platelets to clump together (antiplatelet action). These effects work together to enhance blood flow, particularly in peripheral arteries.

---

Q: What should I do if I forget to take a dose of Плетакс?

Official patient information addresses what to do if a dose is missed. Regulatory documents state that if a dose is remembered soon after the missed time, it may be taken. However, if it is close to the time for the next scheduled dose, the missed dose is typically skipped, and the regular schedule is continued. Taking a double dose to make up for a missed one is advised against.

---

Q: I'm pregnant. Should I stop taking this medication?

Regulatory documents state that use of this medication is contraindicated (prohibited) during pregnancy. Patients who are pregnant, planning to become pregnant, or become pregnant while taking this medication are advised to seek professional advice regarding treatment, as the medicine carries restrictions during pregnancy.

Official Storage and Disposal Instructions

Storage Component	Requirement from Regulatory Documents
Temperature	Store at mathbf25 C (mathbf77 F), allowing excursions between mathbf15 C and mathbf30 C (Controlled Room Temperature).
Environmental Protection	Keep away from excessive heat, moisture, and direct light. Keep from freezing.
Container Rule	Store the medicine in the container it came in, tightly closed.
Child Safety	Keep out of the reach of children.
Disposal Instructions	Dispose of unused or expired medicine through a drug take-back program or by mixing with an undesirable substance (e.g., used coffee grounds) before placing it in household trash. Do not flush the tablets down the toilet.